118 related articles for article (PubMed ID: 29475895)
1. Comprehensive analysis of haemostatic profile depending on clinicopathological determinants in breast cancer patients.
Rhone P; Ruszkowska-Ciastek B; Bielawski K; Brkic A; Zarychta E; Góralczyk B; Roszkowski K; Rość D
Biosci Rep; 2018 Apr; 38(2):. PubMed ID: 29475895
[TBL] [Abstract][Full Text] [Related]
2. Imbalance of plasminogen activator inhibitor-I/ tissue plasminogen activator and tissue factor/tissue factor pathway inhibitor in young Japanese men with myocardial infarction.
Saigo M; Abe S; Ogawa M; Yamashita T; Biro S; Minagoe S; Maruyama I; Tei C
Thromb Haemost; 2001 Nov; 86(5):1197-203. PubMed ID: 11816707
[TBL] [Abstract][Full Text] [Related]
3. Plasma plasminogen activator inhibitor-1 (PAI-1) levels in breast cancer - relationship with clinical outcome.
Ferroni P; Roselli M; Portarena I; Formica V; Riondino S; LA Farina F; Costarelli L; Melino A; Massimiani G; Cavaliere F; Palmirotta R; Guadagni F
Anticancer Res; 2014 Mar; 34(3):1153-61. PubMed ID: 24596353
[TBL] [Abstract][Full Text] [Related]
4. Evaluation of the prognostic value of fibrinolytic elements in invasive breast carcinoma patients.
Ruszkowska-Ciastek B; Kwiatkowska K; Bielawska S; Robakowska M; Bielawski K; Rhone P
Neoplasma; 2020 Sep; 67(5):1146-1156. PubMed ID: 32538669
[TBL] [Abstract][Full Text] [Related]
5. Elevated plasma levels of tissue factor as a valuable diagnostic biomarker with relevant efficacy for prediction of breast cancer morbidity.
Zarychta E; Rhone P; Bielawski K; Rosc D; Szot K; Zdunska M; Ruszkowska-Ciastek B
J Physiol Pharmacol; 2018 Dec; 69(6):. PubMed ID: 30802214
[TBL] [Abstract][Full Text] [Related]
6. Increased plasminogen activator inhibitor-1, decreased tissue factor pathway inhibitor, and unchanged thrombin-activatable fibrinolysis inhibitor levels in patients with primary hyperparathyroidism.
Erem C; Kocak M; Nuhoglu I; Yilmaz M; Ucuncu O
Eur J Endocrinol; 2009 May; 160(5):863-8. PubMed ID: 19233920
[TBL] [Abstract][Full Text] [Related]
7. Tumor expression, plasma levels and genetic polymorphisms of the coagulation inhibitor TFPI are associated with clinicopathological parameters and survival in breast cancer, in contrast to the coagulation initiator TF.
Tinholt M; Vollan HK; Sahlberg KK; Jernström S; Kaveh F; Lingjærde OC; Kåresen R; Sauer T; Kristensen V; Børresen-Dale AL; Sandset PM; Iversen N
Breast Cancer Res; 2015 Mar; 17(1):44. PubMed ID: 25882602
[TBL] [Abstract][Full Text] [Related]
8. Measurement of plasminogen activator system components in plasma and tumor tissue extracts obtained from patients with breast cancer: an EORTC Receptor and Biomarker Group collaboration.
Grebenchtchikov N; Maguire TM; Riisbro R; Geurts-Moespot A; O'Donovan N; Schmitt M; McGreal G; McDermott E; O'Higgins N; Brünner N; Sweep CG; Duffy MJ
Oncol Rep; 2005 Jul; 14(1):235-9. PubMed ID: 15944795
[TBL] [Abstract][Full Text] [Related]
9. Anti-angiogenic efficacy in invasive breast carcinoma patients depends on clinicopathological determinants.
Zarychta E; Rhone P; Bielawski K; Michalska M; Rość D; Ruszkowska-Ciastek B
Adv Med Sci; 2019 Sep; 64(2):216-223. PubMed ID: 30818220
[TBL] [Abstract][Full Text] [Related]
10. The role of tissue factor in patients undergoing open repair of ruptured and nonruptured abdominal aortic aneurysms.
Hobbs SD; Haggart P; Fegan C; Bradbury AW; Adam DJ
J Vasc Surg; 2007 Oct; 46(4):682-6. PubMed ID: 17764874
[TBL] [Abstract][Full Text] [Related]
11. Coagulation and fibrinolysis related cytokine imbalance in preeclampsia: the role of placental trophoblasts.
Teng YC; Lin QD; Lin JH; Ding CW; Zuo Y
J Perinat Med; 2009; 37(4):343-8. PubMed ID: 19290852
[TBL] [Abstract][Full Text] [Related]
12. Prognostic impact of urokinase-type plasminogen activator (PA), PA inhibitor type-1, and tissue-type PA antigen levels in node-negative breast cancer: a prospective study on multicenter basis.
Kim SJ; Shiba E; Kobayashi T; Yayoi E; Furukawa J; Takatsuka Y; Shin E; Koyama H; Inaji H; Takai S
Clin Cancer Res; 1998 Jan; 4(1):177-82. PubMed ID: 9516968
[TBL] [Abstract][Full Text] [Related]
13. Blood coagulation, fibrinolytic activity and lipid profile in subclinical thyroid disease: subclinical hyperthyroidism increases plasma factor X activity.
Erem C
Clin Endocrinol (Oxf); 2006 Mar; 64(3):323-9. PubMed ID: 16487444
[TBL] [Abstract][Full Text] [Related]
14. [Tissue and urokinase plasminogen activators (t-PA, u-PA) and their inhibitor PAI-1 in blood of patients with laryngeal neoplasms].
Białkowska A; Kotschy M; Betlejewski S; Burduk D
Otolaryngol Pol; 1995; 49 Suppl 20():84-7. PubMed ID: 9454229
[TBL] [Abstract][Full Text] [Related]
15. Complex of urokinase-type plasminogen activator with its type 1 inhibitor predicts poor outcome in 576 patients with lymph node-negative breast carcinoma.
Manders P; Tjan-Heijnen VC; Span PN; Grebenchtchikov N; Geurts-Moespot A; van Tienoven DT; Beex LV; Sweep FC
Cancer; 2004 Aug; 101(3):486-94. PubMed ID: 15274061
[TBL] [Abstract][Full Text] [Related]
16. Both the cytosols and detergent extracts of breast cancer tissues are suited to evaluate the prognostic impact of the urokinase-type plasminogen activator and its inhibitor, plasminogen activator inhibitor type 1.
Jänicke F; Pache L; Schmitt M; Ulm K; Thomssen C; Prechtl A; Graeff H
Cancer Res; 1994 May; 54(10):2527-30. PubMed ID: 8168072
[TBL] [Abstract][Full Text] [Related]
17. Potential clinical relevance of uPA and PAI-1 levels in node-negative, postmenopausal breast cancer patients bearing histological grade II tumors with ER/PR expression, during an early follow-up.
Buta M; Džodić R; Đurišić I; Marković I; Vujasinović T; Markićević M; Nikolić-Vukosavljević D
Tumour Biol; 2015 Sep; 36(10):8193-200. PubMed ID: 25994573
[TBL] [Abstract][Full Text] [Related]
18. [Plasminogen activator inhibitor 1 and prognosis in breast carcinoma].
Mayerhofer K; Stolzlechner J; Yildiz S; Haider K; Heinzl H; Jakesz R; Pecherstorfer M; Rosen H; Sevelda P; Zeillinger R; Speiser P
Geburtshilfe Frauenheilkd; 1996 Jan; 56(1):23-7. PubMed ID: 8852782
[TBL] [Abstract][Full Text] [Related]
19. Quantitative RT-PCR assays for the determination of urokinase-type plasminogen activator and plasminogen activator inhibitor type 1 mRNA in primary tumor tissue of breast cancer patients: comparison to antigen quantification by ELISA.
Biermann JC; Holzscheiter L; Kotzsch M; Luther T; Kiechle-Bahat M; Sweep FC; Span PN; Schmitt M; Magdolen V
Int J Mol Med; 2008 Feb; 21(2):251-9. PubMed ID: 18204793
[TBL] [Abstract][Full Text] [Related]
20. Haemostatic factors and intraluminal thrombus thickness in abdominal aortic aneurysm. Is secondary fibrinolysis relevant?
Siennicka A; Drozdzynska M; Chelstowski K; Cnotliwy M; Jastrzebska M
J Physiol Pharmacol; 2013 Jun; 64(3):321-30. PubMed ID: 23959729
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
